Tilray Brands, Inc. (TLRY) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reveals positive financial performance with revenue growth across segments, improved cash flow, and strong liquidity. The Q&A section highlights management's proactive strategies in addressing international growth challenges, potential U.S. market opportunities, and leveraging digital assets. Despite some unclear responses, the overall sentiment is positive, supported by market expansion plans, particularly in Europe and the U.S. The market cap suggests moderate volatility, leading to a prediction of a 2% to 8% stock price increase over the next two weeks.
Key Financial Performance
Net Income $1.5 million, compared to a net loss of $34.7 million in the prior year period. This improvement highlights the company's commitment to sustainable growth and operational efficiency.
Earnings Per Share (EPS) $0.00, compared to negative $0.04 per share in the prior year period. This reflects improved profitability.
Total Revenue $210 million, a 5% increase year-over-year. This growth was driven by double-digit growth in Canadian Adult-Use (12%) and International Cannabis business (10%).
Debt Reduction $7.7 million reduction in outstanding debt, bringing the net debt-to-EBITDA ratio to 0.07x. This reflects efforts to strengthen the balance sheet.
Cash and Cash Equivalents $265 million, showcasing strong liquidity.
Cannabis Revenue $65 million, a 5% year-over-year increase. Growth was driven by 12% growth in adult-use gross revenue and 10% growth in international cannabis.
Canadian Cannabis Revenue $51 million, a 4% year-over-year increase. This was supported by market share growth in key categories such as pre-rolls, beverages, oils, and chocolate edibles.
International Cannabis Revenue $13.4 million, a 10% year-over-year increase. Growth was hindered by delays in obtaining permits in Portugal.
Distribution Revenue $74 million, a 9% year-over-year increase. This was primarily due to a stronger euro.
Beverage Revenue $55.7 million, driven by innovation and SKU rationalization. However, challenges in craft brands and spirits impacted margins.
Wellness Revenue $15.2 million, a 3% year-over-year increase. Growth was driven by new product launches and expanded distribution.
Gross Profit $57.5 million, compared to $59.7 million in the prior year period. Gross margin declined to 27% from 30% due to lower margins in the Beverage and Cannabis businesses.
Adjusted EBITDA $10.2 million, compared to $9.3 million in the prior year period. This reflects improved operational efficiency.
Cash Flow from Operations Negative $1.3 million, a significant improvement from negative $35.3 million in the prior year period.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Revenue growth in Canadian Adult-Use and International Cannabis: Canadian Adult-Use Cannabis grew by 12% and International Cannabis by 10%, contributing to a total revenue increase of 5% year-over-year to $210 million.
New product launches in beverages and wellness: Introduced new non-alcoholic beverages like HiBall and expanded hemp-derived Delta-9 THC beverages. Also launched new wellness products, including high-protein snacks and energy drinks.
Expansion in craft beer and spirits: Launched new craft beer products like Shock Top Ryde pack and expanded partnerships, including co-branded beers with sports teams.
Global cannabis market positioning: Tilray is the #1 Canadian cannabis producer by revenue and holds a 60% market share in branded hemp products in North America. It is also the fourth-largest craft beer producer in the U.S.
European market expansion: Expanded medical cannabis distribution in Germany and Italy, with plans to triple the distribution footprint in Germany in fiscal 2026.
U.S. market potential: Positioned to capture 3%-5% of the $10 billion U.S. medical cannabis market, representing a $300-$500 million opportunity.
Operational efficiencies in Project 420: Achieved $25 million in annual savings, moving closer to the $33 million target.
Debt reduction and cash position: Reduced outstanding debt by $7.7 million, ending the quarter with $265 million in cash and a net debt-to-EBITDA ratio of 0.07x.
Strategic focus on innovation and market leadership: Focused on product innovation in cannabis, beverages, and wellness to meet evolving consumer preferences and regulatory changes.
Regulatory readiness: Prepared to adapt to regulatory changes in the U.S., Canada, and Europe, including potential rescheduling of medical cannabis in the U.S. and regulatory modernization in Canada.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Beverage Segment Performance: Revenue in the Beverage segment remained flat due to deliberate SKU rationalization under Project 420, indicating challenges in optimizing product offerings and market performance.
Cannabis Market Challenges: The cannabis industry faces evolving regulations and market dynamics, with Tilray's gross margin in the Cannabis segment declining from 40% to 36% due to a higher mix of sales in lower-margin categories like infused pre-rolls and vapes.
European Regulatory Delays: Permits in Portugal and other European countries are backlogged, delaying Tilray's ability to ship products and expand its international cannabis market.
Beverage Gross Margin Decline: Gross margin in the Beverage segment decreased from 41% to 38%, attributed to the inclusion of lower-margin craft acquisition sales.
Distribution Gross Margin Pressure: Distribution gross margin declined from 12% to 11% due to changes in product mix, reflecting challenges in maintaining profitability in this segment.
Debt and Financial Flexibility: While Tilray reduced its outstanding debt by $7.7 million, the company raised $22.5 million under its ATM program, which may indicate reliance on external funding to maintain operations and strategic flexibility.
U.S. Medical Cannabis Market Entry: Tilray anticipates capturing a 3%-5% market share in the U.S. medical cannabis market, but this is contingent on regulatory rescheduling, which remains uncertain.
Canadian Regulatory Reforms: Potential regulatory reforms in Canada, such as expanding cannabis in healthcare and on-premise consumption for THC beverages, are still in development and could impact future market opportunities.
International Expansion Risks: Tilray's international expansion strategy, including new beverage and cannabis markets, depends on securing distribution partners and navigating diverse regulatory environments, posing execution risks.
Wellness Business Growth: While the Wellness business grew to $15 million in revenue, it remains a smaller segment, and achieving its full potential will require significant investment and innovation.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
U.S. Medical Cannabis Market Opportunity: Tilray anticipates the U.S. medical cannabis market to be at least a $10 billion market. The company expects to capture a 3% to 5% market share, representing a potential $300 million to $500 million business opportunity.
Canadian Cannabis Market: Tilray foresees substantial potential in Canada due to regulatory reforms, including expanding cannabis in healthcare, broader insurance coverage, on-premise consumption for THC beverages, and regulatory modernization.
European Cannabis Market: Tilray plans to triple its medical cannabis distribution footprint in fiscal 2026, enhancing its reach in the German pharmaceutical market. The company is also expanding its growing capabilities in Portugal and Germany to meet evolving global demand.
International Beverage Expansion: Tilray aims to accelerate the expansion of its non-alcoholic beverages portfolio across multiple international markets. The company has secured a distribution partner in the U.K. for HiBall and is exploring international manufacturing opportunities and potential acquisitions.
U.S. Beverage Business: Tilray is optimizing its beer integration strategy under Project 420, with a goal of achieving $33 million in annual savings. The company is also expanding its hemp-derived Delta-9 THC beverage lines and has established partnerships with major retailers.
Wellness Business Growth: Tilray is focused on expanding its Wellness portfolio, launching new products, and increasing its presence in over 17,000 retailers across the U.S. The company sees significant opportunities for growth in this segment.
Fiscal Year 2026 Guidance: Tilray reaffirms its 2026 guidance, anticipating adjusted EBITDA between $62 million and $72 million.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the current challenges and opportunities in international growth, particularly in Europe?
A:The company is addressing permit delays in Portugal and expects improvements. They are focusing on increasing production capacity in Portugal and Germany, leveraging CC Pharma to distribute medical cannabis to 13,000 drug stores in Germany. The demand in Europe is strong, and they aim to grow their medical cannabis business significantly by 2026.
Q:What is the company's strategy for rescheduling opportunities in the U.S. if cannabis is moved to Schedule III?
A:The company has a strong infrastructure in Canada, including 5 million square feet of facilities and extensive medical cannabis expertise. They are open to partnerships or acquisitions to capture opportunities in the U.S. market. They aim to leverage their existing research, genetics, and know-how.
Q:What is the company's involvement with digital assets like Bitcoin, and what are their plans?
A:The company acquired Bitcoin a few months ago and is exploring other assets like Ethereum and Solana. They plan to enable Bitcoin payments on their websites and are considering tokenizing stock. They see synergies between crypto and their products but do not aim to become a crypto company.
Q:What is the source of cannabis products sold in Europe, and what are the risks related to Germany's regulations?
A:Most products sold in Europe are grown in European facilities, with some coming from Canada and processed in EU GMP-certified facilities. The company is lobbying the German government to ensure continued access for European products in the German market, as changes could disrupt supply.
Q:What is the state of the Canadian adult-use cannabis market, and how is the company performing?
A:The Canadian market is maturing but still has growth potential. The company saw a 12% growth this quarter, with pricing up 2% and volume ahead of the market. They are the only top 5 LP to grow share this quarter. They are advocating for regulatory changes to expand market opportunities.
Q:What are the plans to improve profitability in the beverage segment?
A:The company has taken $25 million in cost reductions and closed three facilities. They are focusing on SKU rationalization, procurement efficiencies, and relisting products in retailers. They aim to make beer more appealing while improving margins.
Q:How is the company managing risks in Portugal and its international strategy?
A:The company is committed to its $200 million facility in Portugal and has seen improvements in permit approvals. They are also leveraging facilities in Germany and Canada to diversify supply and ensure EU GMP compliance.
Q:What are the potential impacts of proposed legislative changes in Germany on the cannabis market?
A:The company is monitoring potential changes but remains optimistic about demand. They believe patients will find ways to access medical cannabis even if online sales are restricted. They are actively lobbying for patient access and market stability.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the timing and exact nature of legislative changes in Germany, as well as the precise steps needed to improve beverage segment profitability. They also used vague language when discussing the broader implications of rescheduling cannabis in the U.S. and the potential impacts of crypto integration.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Broncos
CC Pharma
Delta THC
HD
HiBall
Oregon
Shock Top
Tilray brand
advantage market
cannabis health
care
commitment
country cannabis
craft brand
digit
dollar sale
environment industry
expertise
format
framework
gain
launch
leader
line spirit
market brand
milligram
momentum
offering
opportunity Wellness
opportunity acquisition
opportunity beverage
pack craft
partnership
pharmaceutical
portfolio Project
position category
producer
product consumer
professional
reform development
result Tilray
season
vision
TLRY Transcript
Tilray Brands, Inc. (TLRY) Q3 2026 Earnings Call Transcript
Positive4-1
The earnings call summary and Q&A reflect a positive sentiment overall. The company shows strong international growth, particularly in Europe, and is expanding its distribution footprint. The strategic partnerships and product innovations in the beverage and wellness segments are promising. Despite some uncertainties in cost management and market projections, the reaffirmed EBITDA guidance and strategic plans for cannabis rescheduling in the U.S. and international expansion are positive indicators. The market cap suggests a moderate reaction, leading to a positive stock price movement prediction of 2% to 8%.
Aritzia Inc. (ATZ:CA) Q3 2026 Earnings Call Transcript
Positive1-8
Earnings results show strong financial performance with significant growth in gross profit, EBITDA, and cash position. The successful app launch and international expansion plans further support a positive outlook. Despite some uncertainties in guidance, the overall sentiment from the Q&A is optimistic, with plans for store openings and margin expansion. Given the company's market cap, the stock is likely to experience a positive movement between 2% to 8% over the next two weeks.
Tilray Brands, Inc. (TLRY) Q2 2026 Earnings Call Transcript
Positive1-8
The earnings call highlights several positive elements: strong growth in Canadian and European markets, strategic international expansion, and a focus on higher-margin opportunities. The Q&A session further supports this with insights into market share gains, price stabilization, and a promising outlook for CC Pharma. Despite some challenges in the beer segment, the company's diversified strategy and international growth potential present a positive sentiment. Given the market cap, these factors suggest a likely positive stock price movement in the short term.
Tilray Brands, Inc. (TLRY) Q1 2026 Earnings Call Transcript
Positive10-9
The earnings call summary reveals positive financial performance with revenue growth across segments, improved cash flow, and strong liquidity. The Q&A section highlights management's proactive strategies in addressing international growth challenges, potential U.S. market opportunities, and leveraging digital assets. Despite some unclear responses, the overall sentiment is positive, supported by market expansion plans, particularly in Europe and the U.S. The market cap suggests moderate volatility, leading to a prediction of a 2% to 8% stock price increase over the next two weeks.
TLRY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
